A model to predict survival in patients with end-stage liver disease
Citations
6,642 citations
5,557 citations
1,705 citations
Additional excerpts
...0001 MELD score (n 268) 36 (11-53) 28 (7-52) <....
[...]
...Age (years) 38 (18-76) 131 34 (17-68) 122 Sex (% female) 96 (73%) 131 90 (74%) 122 Survival without transplantation 84 (64%) 131 80 (66%) 122 Liver transplantation 12 (9%) 131 8 (7%) 122 Listed for liver transplantation 35 (27%) 130 30 (25%) 122 Days from admission to transplantation 3 (1-7) 11 3 (2-5) 7 Overall short-term (3-week) survival 94 (72%) 131 87 (71%) 122 NAC treatment given 125 (95%) 131 106 (87%) 122 Cause of pain reported* 107 (81%) 116 0 (0%) 122 Total acetaminophen dose (g) 20 (2....
[...]
...Age (yrs) 37 (17-76) Sex, n (% female) 204 (74%) Race White 242 (88%) African American 15 (5%) Asian 6 (2%) Hispanic 5 (2%) Native American 3 (1%) Other 4 (2%) Overdose Type Unintentional 131 (48%) Intentional 122 (44%) Unknown 22 (8%) Serum acetaminophen level, g/dL (n 257) 31 (0-644) Acetaminophen dose, g (n 179) 24 (1....
[...]
...2-90) 91 Serum acetaminophen ( g/dL) 18 (0-400) 119 64 (0-644) 118 Narcotic/acetaminophen use 83 (63%) 131 22 (18%) 122 Antidepressant use 48 (37%) 131 46 (38%) 122 Serum ALT (U/L) 3,319 (126-18,079) 130 5,326 (179-19,826) 122 Platelets (thousands/ L) 126 (15-699) 131 120 (5-447) 120 Admission Hepatic Coma stage 3 (1-4) 131 2 (1-4) 118 Admission Hepatic Coma (stages 3-4) 72 (55%) 131 47 (39%) 122 Peak hepatic coma stage 3 (1-4) 131 3 (1-4) 120 Peak hepatic coma (stages 3-4) 89 (68%) 131 72 (59%) 122 Met King’s criteria 26 (20%) 131 8 (7%) 122 Creatinine 2 74 (57%) 131 53 (43%) 122 INR 3 56 (42%) 131 68 (56%) 122 ALT 3,500 63 (48%) 131 88 (72%) 122 Bilirubin 4 73 (56%) 131 74 (61%) 122 MELD 20 113 (88%) 129 102 (87%) 117 APACHE II 15 75 (66%) 113 49 (57%) 86 BMI 25 (17-51) 97 24 (16-56) 99...
[...]
1,657 citations
1,488 citations
References
19,398 citations
14,211 citations
7,262 citations
2,479 citations
Additional excerpts
...MELD 9 (4-14) 10 (8-13) 1 (22-5) 7 (3-13)...
[...]